|
The
following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they
would be anti-dilutive:
Schedule
of Potentially Dilutive Securities
| |
|
2023 |
|
|
2022 |
|
| |
|
June
30, |
|
| |
|
2023 |
|
|
2022 |
|
| Common
stock warrants August 2021 |
|
|
2,827,708 |
|
|
|
2,827,708 |
|
| Underwriter
warrants August 2021 |
|
|
50,416 |
|
|
|
50,416 |
|
| Private
warrants |
|
|
— |
|
|
|
7,549 |
|
| Chanticleer
warrants |
|
|
1,267 |
|
|
|
1,267 |
|
| Series
C warrants |
|
|
809,243 |
|
|
|
809,243 |
|
| Series
3 warrants |
|
|
276,140 |
|
|
|
— |
|
| Unvested
restricted stock units and awards |
|
|
172,667 |
|
|
|
48,156 |
|
| Common
stock warrants February 2023 |
|
|
5,981,482 |
|
|
|
— |
|
| Underwriter
warrants February 2023 |
|
|
972,222 |
|
|
|
— |
|
| Common
stock private placement warrants June 2023 |
|
|
5,000,000 |
|
|
|
— |
|
| PA
warrants June 2023 |
|
|
150,000 |
|
|
|
— |
|
| Total
anti-dilutive weighted average shares |
|
|
16,241,145 |
|
|
|
3,744,339 |
|
|